API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://endpts.com/stealth-bio-gets-fda-adcomm-for-previously-rejected-ultra-rare-disease-drug/
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-acceptance-of-new-drug-application-for-elamipretide-for-the-treatment-of-barth-syndrome-302109608.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-positive-end-of-phase-2-meeting-with-fda-on-the-development-of-elamipretide-in-patients-with-dry-age-related-macular-degeneration-301848690.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-enters-into-exclusive-licensing-agreement-with-pharmanovia-to-commercialize-elamipretide-for-the-treatment-of-barth-syndrome-in-europe-and-key-global-territories-301836759.html
https://www.fiercebiotech.com/biotech/after-backdoor-attempt-stealth-will-try-old-fashioned-fda-business-meeting-save
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-data-from-the-phase-2-reclaim-2-study-of-elamipretide-in-geographic-atrophy-at-the-clinical-trials-at-the-summit-meeting-2022-301552607.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-receives-orphan-drug-designation-from-fda-for-elamipretide-for-treatment-of-duchenne-muscular-dystrophy-301545679.html
https://www.benzinga.com/general/biotech/22/05/26928497/stealth-bio-posts-disappointing-elamipretide-data-from-mid-stage-geographic-atrophy-study
https://www.prnewswire.com/news-releases/last-patient-completes-treatment-in-stealth-biotherapeutics-phase-2-geographic-atrophy-clinical-trial-301481918.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-oral-presentation-of-new-duchenne-muscular-dystrophy-data-at-the-2022-muscular-dystrophy-association-clinical-and-scientific-conference-301476934.html
https://www.marketwatch.com/story/stealth-biotherapeutics-shares-drop-12-after-fda-refusal-to-file-letter-271634748116
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-receives-refusal-to-file-letter-from-the-fda-301404174.html
https://pink.pharmaintelligence.informa.com/PS144891/Stealth-Elamipretide-NDA-Tests-Frontiers-Of-US-FDAs-Flexibility-In-Rare-Diseases
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases-301189822.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-20-million-financing-to-advance-development-of-elamipretide-and-pipeline-301039158.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-positive-results-from-study-to-evaluate-efficacy-of-elamipretide-in-barth-patients-compared-to-natural-history-control-301006308.html
https://www.biospace.com/article/stealth-ceo-shares-excitement-about-alexion-partnership-and-potential-of-pmm-drug/?s=95
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-presents-data-for-elamipretide-on-cardiac-function-in-barth-syndrome-300940138.html
https://www.fiercebiotech.com/biotech/alexion-bags-option-stealth-s-phase-3-rare-disease-drug
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-positive-results-for-elamipretide-in-ophthalmic-conditions-300841246.html
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd-300820226.html